RT Journal Article
SR Electronic
T1 People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.22.22272793
DO 10.1101/2022.03.22.22272793
A1 Lapointe, Hope R.
A1 Mwimanzi, Francis
A1 Cheung, Peter K.
A1 Sang, Yurou
A1 Yaseen, Fatima
A1 Umviligihozo, Gisele
A1 Kalikawe, Rebecca
A1 Speckmaier, Sarah
A1 Moran-Garcia, Nadia
A1 Datwani, Sneha
A1 Duncan, Maggie C.
A1 Agafitei, Olga
A1 Ennis, Siobhan
A1 Young, Landon
A1 Ali, Hesham
A1 Ganase, Bruce
A1 Omondi, F. Harrison
A1 Dong, Winnie
A1 Toy, Junine
A1 Sereda, Paul
A1 Burns, Laura
A1 Costiniuk, Cecilia T.
A1 Cooper, Curtis
A1 Anis, Aslam H.
A1 Leung, Victor
A1 Holmes, Daniel
A1 DeMarco, Mari L.
A1 Simons, Janet
A1 Hedgcock, Malcolm
A1 Prystajecky, Natalie
A1 Lowe, Christopher F.
A1 Pantophlet, Ralph
A1 Romney, Marc G.
A1 Barrios, Rolando
A1 Guillemi, Silvia
A1 Brumme, Chanson J.
A1 Montaner, Julio S.G.
A1 Hull, Mark
A1 Harris, Marianne
A1 Niikura, Masahiro
A1 Brockman, Mark A.
A1 Brumme, Zabrina L.
YR 2022
UL http://medrxiv.org/content/early/2022/03/23/2022.03.22.22272793.abstract
AB Background Longer-term humoral responses to two-dose COVID-19 vaccines remain incompletely characterized in people living with HIV (PLWH), as do initial responses to a third dose.Methods We measured antibodies against the SARS-CoV-2 spike protein receptor-binding domain, ACE2 displacement and viral neutralization against wild-type and Omicron strains up to six months following two-dose vaccination, and one month following the third dose, in 99 PLWH receiving suppressive antiretroviral therapy, and 152 controls.Results Though humoral responses naturally decline following two-dose vaccination, we found no evidence of lower antibody concentrations nor faster rates of antibody decline in PLWH compared to controls after accounting for sociodemographic, health and vaccine-related factors. We also found no evidence of poorer viral neutralization in PLWH after two doses, nor evidence that a low nadir CD4+ T-cell count compromised responses. Post-third-dose humoral responses substantially exceeded post-second-dose levels, though anti-Omicron responses were consistently weaker than against wild-type.Nevertheless, post-third-dose responses in PLWH were comparable to or higher than controls. An mRNA-1273 third dose was the strongest consistent correlate of higher post-third-dose responses.Conclusion PLWH receiving suppressive antiretroviral therapy mount strong antibody responses after two- and three-dose COVID-19 vaccination. Results underscore the immune benefits of third doses in light of Omicron.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funding from Genome BC, the Michael Smith Foundation for Health Research, and the BCCDC Foundation for Public Health through a rapid SARS-CoV-2 vaccine research initiative in BC award (VAC-009 to ZLB, MAB). It was also supported by the Public Health Agency of Canada (PHAC) through two COVID-19 Immunology Task Force (CITF) COVID-19 Awards (to ZLB, MGR, MAB and to CTC, CC, AHA), the Canada Foundation for Innovation through Exceptional Opportunities Fund COVID-19 awards (to CJB, CFL, MAB, MN, MLD, RP, ZLB), a British Columbia Ministry of Health Providence Health Care Research Institute COVID-19 Research Priorities Grant (to CJB and CFL), the CIHR Canadian HIV Trials Network (CTN) (to AHA) and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (R01AI134229 to RP). MLD and ZLB hold Scholar Awards from the Michael Smith Foundation for Health Research. FA was supported by an SFU Undergraduate Research Award. GU and FHO are supported by Ph.D. fellowships from the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative [grant # DEL-15-006]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS) Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africas Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [grant # 107752/Z/15/Z] and the UK government. The views expressed in this publication are those of the authors and not necessarily those of PHAC, CITF, AAS, NEPAD Agency, Wellcome Trust, the Canadian or UK governments or other funders.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants provided written informed consent. This study was approved by the University of British Columbia/Providence Health Care and Simon Fraser University Research Ethics Boards.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors